https://ir.vyometx.com/ https://ir.vyometx.com/news-events/press-releases https://ir.vyometx.com/news-events/ir-calendar https://ir.vyometx.com/news-events/presentations https://ir.vyometx.com/news-events/email-alerts https://ir.vyometx.com/company-information https://ir.vyometx.com/company-information/contacts https://ir.vyometx.com/company-information/faq https://ir.vyometx.com/financial-information/financial-results https://ir.vyometx.com/financial-information/income-statement https://ir.vyometx.com/financial-information/balance-sheet https://ir.vyometx.com/financial-information/cash-flow https://ir.vyometx.com/stock-data/quote-chart https://ir.vyometx.com/stock-data/historical-data https://ir.vyometx.com/stock-data/analyst-coverage https://ir.vyometx.com/sec-filings/all-sec-filings https://ir.vyometx.com/sec-filings/annual-reports https://ir.vyometx.com/sec-filings/quarterly-reports https://ir.vyometx.com/sec-filings/section-16-filings https://ir.vyometx.com/governance https://ir.vyometx.com/governance/board-committees https://ir.vyometx.com/governance/governance-documents https://ir.vyometx.com/news-events/press-releases/detail/106/vyome-holdings-reports-first-quarter-2026-results-with-key-fda-filings-and-strong-balance-sheet 2026-05-28T08:00:03-04:00 https://ir.vyometx.com/news-events/press-releases/detail/105/vyome-strikes-deal-with-impetis-biosciences-opening-a-~57b-market-opportunity 2026-05-12T08:00:05-04:00 https://ir.vyometx.com/news-events/press-releases/detail/85/vyome-presents-transformational-vt-1953-phase-2-clinical-study-data-at-prestigious-aacr-2026 2026-04-22T11:29:31-04:00 https://ir.vyometx.com/news-events/press-releases/detail/86/vyome-to-present-compelling-phase-2-clinical-data-on-vt-1953-for-treatment-of-mfw-at-aacr-2026 2026-04-22T11:29:31-04:00 https://ir.vyometx.com/news-events/press-releases/detail/87/vyome-reports-transformational-2025-results-company-well-positioned-for-breakout-phase 2026-04-22T11:29:31-04:00 https://ir.vyometx.com/news-events/press-releases/detail/88/livechain-completes-acquisition-of-senior-secured-debt-of-humanyze-an-mit-incubated-ai-enabled-hr-analytics-company 2026-04-22T11:29:31-04:00 https://ir.vyometx.com/news-events/press-releases/detail/89/vyome-announces-the-publication-of-positive-preclinical-results-in-uveitis-addressing-a-3b-potential-market-opportunity 2026-04-22T11:29:31-04:00 https://ir.vyometx.com/news-events/press-releases/detail/90/vyome-files-for-vt-1953-orphan-drug-status-furthers-strategic-focus-on-vt-1953-program-over-the-next-6-months 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/91/vyome-successfully-capitalizes-all-vt-1953-funding-requirements-for-initial-phase-3-results 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/92/independent-analyst-values-vyomes-vt-1953-at-usd-1-billion-upon-successful-completion-of-phase-3-study 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/93/vyome-subsidiary-livechain-lich-to-acquire-senior-secured-note-in-humanyze-an-mit-incubated-company 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/94/vyome-reports-positive-final-phase-2-results-for-vt-1953-plans-to-advance-into-pivotal-study-for-fda-approval 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/95/vyome-appoints-renowned-medical-oncologist-dr-aditya-bardia-as-senior-medical-advisor-to-guide-the-development-of-mfw-program 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/96/vyome-holdings-announces-transformational-first-quarter-following-nasdaq-listing 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/97/vyome-holdings-announces-results-of-annual-shareholder-meeting 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/98/vyome-holdings-acquires-mit-ai-spinout-oculo-health 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/99/vyome-presents-strong-data-showing-topical-vt-1908-is-an-effective-treatment-for-uveitis-opening-up-a-3b-addressable-market-opportunity 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/100/vyome-holdings-strengthens-leadership-team-with-industry-veterans-as-it-plans-pivotal-trial-studies 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/101/vyome-holdings-announces-positive-interim-data-from-phase-2-study-of-vt-1953-in-malignant-fungating-wounds-mfw-and-provides-update-on-mfw-market-opportunity 2026-04-22T11:29:32-04:00 https://ir.vyometx.com/news-events/press-releases/detail/102/vyome-signs-mou-with-embryyo-indias-leading-medical-device-innovation-studio 2026-04-22T11:29:33-04:00 https://ir.vyometx.com/news-events/press-releases/detail/103/vyome-announces-strategic-review-of-livechain-otcid-lich 2026-04-22T11:29:33-04:00 https://ir.vyometx.com/news-events/press-releases/detail/104/vyome-to-mark-first-day-of-trading-as-hind-with-nasdaq-opening-bell 2026-04-22T11:29:33-04:00 https://ir.vyometx.com/news-events/ir-calendar/detail/20260603-first-quarter-2026-earnings-call 2026-06-04T14:10:06-04:00 https://ir.vyometx.com/news-events/ir-calendar/detail/20260330-fourth-quarter-and-full-year-2025-financial-results-and-corporate-update 2026-04-27T17:31:39-04:00 https://ir.vyometx.com/sec-filings/all-sec-filings/content/0001213900-26-062458/ea0292643-8k_vyome.htm 2026-05-29T08:43:20-04:00 https://ir.vyometx.com/sec-filings/all-sec-filings/content/0001213900-26-055058/ea0289466-10q_vyome.htm 2026-05-12T16:05:03-04:00 https://ir.vyometx.com/sec-filings/all-sec-filings/content/0001213900-26-049312/ea0288267-8k_vyome.htm 2026-04-29T16:18:37-04:00 https://ir.vyometx.com/sec-filings/all-sec-filings/content/0001213900-26-036740/ea0282811-02.htm 2026-04-22T13:44:25-04:00 https://ir.vyometx.com/sec-filings/all-sec-filings/content/0001213900-26-032407/ea0282811-pre14a_vyome.htm 2026-04-22T13:44:14-04:00 https://ir.vyometx.com/sec-filings/all-sec-filings/content/0001213900-26-029500/ea0280821-10k_vyomehold.htm 2026-04-22T13:43:41-04:00 https://ir.vyometx.com/sec-filings/all-sec-filings/content/0001213900-26-020387/ea0277935-8k_vyome.htm 2026-04-22T13:42:03-04:00 https://ir.vyometx.com/news-events/presentations/detail/34490/u-s-market-product-assessment-and-valuation-of-vt-1953-for-the-treatment-of-symptoms-of-malignant-fungating-wounds-h1-2026 2026-01-27T00:00:00-05:00 https://ir.vyometx.com/news-events/presentations/detail/34489/vt-1953-in-treating-symptoms-of-malignant-fungating-wounds-mfw 2026-02-12T00:00:00-05:00 https://ir.vyometx.com/disclaimer https://ir.vyometx.com/sitemap https://ir.vyometx.com/accessibility-statement